Janssen Pharmaceutica Nv

Ortho-mcneil Pharmaceutical Corp.

Ning Qin

Christopher M Flores

Ellen Codd

Scott L Dax

Mark Andrew Youngman

Christopher A Teleha

Jay M Matthews

Raymond W Colburn

Yi Liu

Mark J Macielag

James J McNally

Donald William Ludovici

Kenneth M Wells

Michele C Jetter

Ronald K Russell

Shawn T Branum

Michael R D'Andrea

Scott C Youells

Michael P Neeper

Laura Reany

Laura M Reaney

Sui-Po Zhang

Tasha Hutchinson

Mary Lou Lubin

Laura W Andraka

Laura M Andraka

Ellen E Codd

James J Mcnally

Laura M Reany

Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula I as follows: wherein A, B, G, Y, R, R, R, and Rare defined herein.

Sulfonamides as TRPM8 modulators

The invention is directed to TRPM8 antagonists of Formula (I). More specifically, the present invention relates to certain novel compounds, methods for preparing compounds, compositions, intermediates and derivatives thereof and methods for treating TRPM8-mediated disorders. Pharmaceutical and veterinary compositions and methods of treating pain and various other disease states or conditions using compounds of the invention are also described.

Cold menthol receptor-1 antagonists

The present invention discovered that a mammalian TRPM8 binds to calmodulin. The present invention provides a polypeptide complex comprising a cold-menthol receptor (TRPM8) or an active fragment or derivative of TRPM8 and a calmodulin or an active fragment or derivative of calmodulin, and the uses of the polypeptide complex.

Polypeptide complex of TRPM8 and calmodulin and its uses thereof

A recombinant canine TRPV2 channel which has been prepared by cDNA cloning and polymerase chain reaction techniques is disclosed. Expression systems for these channels and an assay using the expression systems are also disclosed. The recombinant TRPV2 channel can be used in assays to evaluate compounds which directly or indirectly interact with or bind to TRPV2 channel.

Canine transient receptor potential V2 (cTRPV2) and methods of screening for TRPV2 channel modulators

The present invention provides nucleic acid and polypeptide sequences describing an isoform of the &#x3b1;2&#x3b4;-4 subunit of a voltage gated calcium channel. The nucleic acids described herein can be used to produce functional &#x3b1;2&#x3b4;-4 protein. The calcium channel &#x3b1;2&#x3b4;-4 protein may be isolated for the purposes of binding experiments or may be used in cells to form a functional calcium channel complex.

CDNA encoding the human &#x3b1;2 &#x3b4;4 calcium channel subunit

It has now been discovered that certain cannabinoids specifically activate TRPV2 channel activity. Based on the discovery, novel compositions and methods for screening, identifying and characterizing compounds that increase or decrease the biological activity of a TRPV2.

Compositions and methods for identifying modulators of TRPV2

CDNA encoding the human alpha2 delta4 calcium channel subunit

The present invention provides nucleic acid and polypeptide sequences describing a neve isozyme of the cyclooxygenase enzyme, herein named as human cyclooxygenase 3. The isolated nucleic acid or polypeptide molecule of the invention can be used in detection assays, gene therapy, and screening assays.

Human cyclooxygenase-3 enzyme and uses thereof

DNAs encoding human voltage gated sodium channel &#x3b2;1A subunit have been cloned and characterized. The recombinant protein is capable of forming biologically active protein. The cDNA's have been expressed in recombinant host cells that produce active recombinant protein. The recombinant protein is also purified from the recombinant host cells. In addition, the recombinant host cells are utilized to establish a method for identifying modulators of the receptor activity, and receptor modulators are identified.

Human voltage gated sodium channel &#x3b2;1A subunit and methods of use

The present invention provides nucleic acid and polypeptide sequences describing a novel canine cold- and menthol-sensitive receptor, herein named as canine CMR1 (cCMR1). The isolated nucleic acid or polypeptide molecule of the invention can be used in detection assays and screening assays.

Canine cold- and menthol-sensitive receptor 1

The present invention provides nucleic acid and polypeptide sequences describing a novel isoform of the &#x3b1;2&#x3b4; subunit of a voltage gated calcium channel, herein named as &#x3b1;2&#x3b4;-4. The isolated nucleic acid or polypeptide molecule of the invention can be used in diagnosing and treating a disease or disorder associated with a defective &#x3b1;2&#x3b4;-4 subunit, such as seizure-related syndromes, anxiety, multiple sclerosis, and the like.

Growing community of inventors

Blue Bell, PA, United States of America

Ning Qin